Skip to main content

Table 1 Baseline characteristics of the study patients

From: Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis

  

Raloxifene

No treatment

P value

Age (years)

 

74.24 ± 7.62

72.52 ± 9.70

0.238

Body mass index (kg/m2)

 

22.80 ± 4.82

24.12 ± 4.85

0.116

Survival years

 

8.06 ± 2.63

6.11 ± 4.33

0.004

Fracture no (spine)

 

1.83 ± 1.07

1.48 ± 1.48

0.158

Previous hip fracture

No

46(90.2 %)

88(89.8 %)

0.592

 

Yes

5(9.8 %)

10(10.2 %)

 

Diabetes

No

38(74.5 %)

73(74.5 %)

0.581

 

Yes

13(25.5 %)

25(25.5 %)

 

Hypertension

No

25(49.0 %)

46(46.9 %)

0.864

 

Yes

26(51.0 %)

52(53.1 %)

 

Neurological disease

No

50(98.0 %)

97(99.0 %)

1

 

Yes

1(2.0 %)

1(1.0 %)

 

Pulmonary disease

No

49(96.1 %)

92(93.9 %)

0.716

 

Yes

2(3.9 %)

6(6.1 %)

 

Cardiovascular disease

No

49(96.1 %)

93(94.9 %)

1

 

Yes

2(3.9 %)

5(5.1 %)

 

Liver disease

No

47(92.2 %)

91(92.9 %)

1

 

Yes

4(7.8 %)

7(7.1 %)